publication date: Mar. 4, 2016
Imbruvica Granted 5th Approval, For First-Line CLL Patients
FDA approved Imbruvica (ibrutinib) as a first-line treatment for patients with chronic lymphocytic leukemia.
The approval is based on data from the randomized, multi-center, open-label phase III RESONATE-2 trial, which evaluated the use of Imbruvica versus chlorambucil in 269 treatment-naïve patients with CLL or small lymphocytic lymphoma aged 65 years or older. The data were previously presented at the annual meeting of the American Society of Hematology in December 2015 and also published in The New England Journal of Medicine.
Imbruvica is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech Inc.
Imbruvica is now approved to treat CLL patients regardless of their treatment history, as well as to treat high-risk CLL patients with del17p. This is the fifth treatment indication for Imbruvica.
RESONATE-2 showed Imbruvica significantly improved progression-free survival and overall response rate compared to chlorambucil in treatment-naïve patients aged 65 or older with CLL or small lymphocytic lymphoma. The data indicated an 84 percent reduction in the risk of death or progression in the Imbruvica arm versus the chlorambucil arm (HR=0.161 [95% CI, 0.091-0.283]). Median PFS was not reached for Imbruvica, versus 18.9 months for chlorambucil (95 percent CI: 14.1, 22.0).
Health Canada approved Opdivo injection (nivolumab), the first and only immuno-oncology therapy approved in Canada for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy.
Continue reading 42-09 Imbruvica Granted 5th Approval, For First-Line CLL Patients
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.